Qualigen Therapeutics, Inc. (QLGN)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today?
Qualigen Therapeutics (NASDAQ: QLGN ) stock is falling on Monday as the clinical-stage therapeutics company's shares come off of a massive rally on Friday. That Friday rally resulted in shares of QLGN stock closing out normal trading hours up 109.2%.
Why Is Qualigen (QLGN) Stock Up 141% Today?
Qualigen (NASDAQ: QLGN ) stock is rocketing higher on Friday after the clinical-stage therapeutics company secured a new loan. Qualigen reached an agreement with an investor for a $2 million Senior Note due July 8, 2025 with an 18% annual interest rate.
Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today?
Qualigen Therapeutics (NASDAQ: QLGN ) stock is sliding lower on Monday as the clinical-stage therapeutics company's shares come off of a rally on Friday. That rally saw shares of QLGN stock soar more than 59% higher during normal trading hours.
Qualigen Therapeutics, Inc. (QLGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Qualigen Therapeutics, Inc. ever had a stock split?
Qualigen Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Kevin A. Richardson II CEO | NASDAQ (CM) Exchange | 74754R103 CUSIP |
| US Country | 4 Employees | - Last Dividend | 23 Mar 2018 Last Split | 24 Jun 2015 IPO Date |
Overview
Qualigen Therapeutics, Inc. is a biotechnology firm established in 1996 and headquartered in Carlsbad, California. The company is committed to developing and commercializing innovative treatments for cancer and infectious diseases. Leveraging its expertise in biotechnology, Qualigen Therapeutics focuses on bringing novel therapeutic products to market, aiming to address some of the most challenging medical conditions with a focus on quality and speed. Their cutting-edge approach includes the development of drugs and therapeutic devices, heavily relying on both proprietary technologies and innovative research in the field.
Products and Services
- FastPack System - A patented, rapid onsite immunoassay testing system designed to improve diagnostic efficiency and accuracy. This product underscores the company's commitment to advancing diagnostic technologies alongside therapeutic products.
- QN-302 - Currently under development, QN-302 is targeted for the treatment of pancreatic ductal adenocarcinoma, a challenging and often deadly form of cancer. This exemplifies Qualigen's focus on targeted cancer therapies.
- QN-247 - An oligonucleotide-based drug candidate intended to treat a variety of cancers that express nucleolin, including both liquid and solid tumors. This approach reflects the company's strategy to tackle cancer through innovative molecular targeting.
- QN-165 - A drug candidate viewed as a potential broad-spectrum solution for infectious diseases, including COVID-19. Its development underscores the company's commitment to addressing urgent global health challenges.
- RAS-F - A small-molecule inhibitor targeting the RAS oncogene protein-protein interactions. By blocking RAS mutations and inhibiting tumor formation, RAS-F represents a novel approach to cancer treatment, reflecting Qualigen's focus on cutting-edge research in oncology.
- Selective Target Antigen Removal System - This therapeutic device is designed to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints from the body. It highlights Qualigen's innovative approach to treatment, aiming at directly eliminating the sources of disease.
Contact Information
